Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Verhoef TI, et al. Among authors: kamali f. Pharmacogenomics. 2012 Sep;13(12):1405-17. doi: 10.2217/pgs.12.124. Pharmacogenomics. 2012. PMID: 22966889 Review.
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland van der Zee AH. van Schie RM, et al. Among authors: kamali f. Pharmacogenomics. 2009 Oct;10(10):1687-95. doi: 10.2217/pgs.09.125. Pharmacogenomics. 2009. PMID: 19842940 Clinical Trial.
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.
Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group. Verhoef TI, et al. Among authors: kamali f. Pharmacogenomics. 2010 Jul;11(7):989-1002. doi: 10.2217/pgs.10.74. Pharmacogenomics. 2010. PMID: 20602617 Review.
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.
Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium. Marvig CL, et al. Among authors: kamali f. Thromb Res. 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. Epub 2015 Apr 25. Thromb Res. 2015. PMID: 25956287 Clinical Trial.
A randomized trial of genotype-guided dosing of warfarin.
Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. Pirmohamed M, et al. Among authors: kamali f. N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251363 Free article. Clinical Trial.
Patients benefit from genetics-guided coumarin anticoagulant therapy.
Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulous VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M; EU-PACT Study Group. Maitland-van der Zee AH, et al. Among authors: kamali f. Clin Pharmacol Ther. 2014 Jul;96(1):15-7. doi: 10.1038/clpt.2014.44. Clin Pharmacol Ther. 2014. PMID: 24942396
224 results